Proactive Investors - Run By Investors For Investors

AstraZeneca confirms full-year guidance; CEO says results mark an important milestone

Total revenues were still stuck in reverse gear, but the underlying picture, measured by product sales, was healthier with the figure up 8% to US$5.27bn
test tubes
The UK's second-largest drugs group believes it has found the formula for success

AstraZeneca PLC (LON:AZN) said it was still on track to hit full-year guidance even after its earnings undershoot for the third-quarter.

Pre-tax profit dropped 36% to U$477mln in the three months ended September. This gave reported EPS of 37 cents a share, some 3 cents shy of consensus.

READ: AstraZeneca sells off three more non-core drugs for US$370mln

The drug giant’s total revenues declined 14% in the period to US$5.34bn, reflecting AZ’s decision to sell or outsource some of its older business lines.

The underlying picture, measured by product sales, was healthier with the figure up 8% to US$5.27bn.

Stand-out was the performance of the emerging markets business, which is now the company’s biggest operation, while the oncology arm saw its sales increase by over a half.

AZ currently has one of the strongest product pipelines among the drug majors with five recently-approved drugs coming onto the market, a further six awaiting the regulatory green light and six undergoing phase III trials.

Chief executive Pascal Soriot believes the UK’s second-largest pharma company is set for a “period of sustained growth for years to come”.

“Commercial execution has been exceptional and our new medicines are now firmly established as the drivers of growth, supporting our continued success in emerging markets,” he added.

View full AZN profile View Profile

AstraZeneca Timeline

Article
November 16 2018

Related Articles

Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago
mri scanner
September 12 2018
IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis
bacteria
December 17 2018
Summit has big plans for its flagship ridinilazole C. Diff treatment as well as its gonorrhoea and hospital superbug candidates this year, and it now has the funds to develop all of them as intended

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use